Regeneron Pharmaceuticals, Inc. (REGN) director Joseph Goldstein, Sold $325,600 in Stock; Issuer Direct (NYSEAMERICAN:ISDR) Shorts Down By 50%

Issuer Direct Corporation (NYSEAMERICAN:ISDR) had a decrease of 50% in short interest. ISDR’s SI was 500 shares in February as released by FINRA. Its down 50% from 1,000 shares previously. With 5,900 avg volume, 0 days are for Issuer Direct Corporation (NYSEAMERICAN:ISDR)’s short sellers to cover ISDR’s short positions. The SI to Issuer Direct Corporation’s float is 0.03%. It closed at $17.15 lastly. It is down 123.64% since February 14, 2017 and is uptrending. It has outperformed by 106.94% the S&P500.

Joseph Goldstein who is the present director of Regeneron Pharmaceuticals Inc recently sold 1,000 shares of the public firm. The insider deal has $325,600 USD total value, at an average stock price per share of $325.6. Today, Joseph Goldstein owns 12,000 shares or 0.01% of the Company’s market capitalization (total value of the shares outstanding).

Investors sentiment decreased to 1 in Q3 2017. Its down 4.00, from 5 in 2017Q2. It is negative, as 0 investors sold Issuer Direct Corporation shares while 3 reduced holdings. 2 funds opened positions while 1 raised stakes. 136,884 shares or 46.20% less from 254,442 shares in 2017Q2 were reported. Geode Capital Mgmt Ltd Liability Com owns 0% invested in Issuer Direct Corporation (NYSEAMERICAN:ISDR) for 35,897 shares. Blackrock accumulated 6,883 shares. Deutsche Retail Bank Ag holds 0% or 18,141 shares. Advisory Ser Networks Lc stated it has 4 shares. Bridgeway Capital holds 0% or 25,000 shares. Comerica Comml Bank invested in 0% or 12,500 shares. Morgan Stanley stated it has 1,700 shares or 0% of all its holdings. Renaissance Tech Ltd Liability Co has invested 0% in Issuer Direct Corporation (NYSEAMERICAN:ISDR). Acadian Asset Mngmt Limited Liability Corporation owns 2,221 shares. Vanguard Grp has 0% invested in Issuer Direct Corporation (NYSEAMERICAN:ISDR).

Issuer Direct Corporation provides disclosure management solutions, shareholder communications tools, and cloud compliance technologies in North America and Europe. The company has market cap of $51.12 million. It offers services and products that enable companies' to produce and distribute their financial and business communications online and in print. It has a 31.3 P/E ratio. The firm provides Platform id, a cloud communications and compliance system for corporate issuers, mutual funds, and compliance professionals.

The stock decreased 5.28% or $18.1 during the last trading session, reaching $324.57. About 1.56M shares traded or 68.02% up from the average. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since February 14, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.

Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 14 have Buy rating, 1 Sell and 18 Hold. Therefore 42% are positive. Regeneron Pharmaceuticals Inc. has $700 highest and $300 lowest target. $490.12’s average target is 51.01% above currents $324.57 stock price. Regeneron Pharmaceuticals Inc. had 117 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Robert W. Baird on Friday, August 5. On Monday, September 4 the stock rating was maintained by Jefferies with “Hold”. As per Tuesday, August 4, the company rating was maintained by Chardan Capital Markets. Piper Jaffray maintained the shares of REGN in report on Sunday, February 11 with “Buy” rating. As per Wednesday, January 20, the company rating was initiated by Credit Suisse. As per Monday, August 31, the company rating was downgraded by Chardan Capital Markets. The stock has “Neutral” rating by Citigroup on Friday, December 1. The stock has “Outperform” rating by Raymond James on Tuesday, September 1. Credit Suisse downgraded the stock to “Hold” rating in Friday, July 14 report. The rating was maintained by UBS with “Sell” on Wednesday, August 5.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide. The company has market cap of $34.90 billion. The Company’s products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It has a 31.39 P/E ratio. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.

Since August 16, 2017, it had 2 insider purchases, and 6 sales for $85.83 million activity. Sanofi had bought 166,415 shares worth $80.03 million on Wednesday, August 23. $900,000 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was sold by BAKER CHARLES A on Friday, September 29. Landry Robert E had sold 468 shares worth $222,981. $7.14M worth of stock was sold by VAGELOS P ROY on Wednesday, August 16. BROWN MICHAEL S had sold 1,500 shares worth $712,500.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.21, from 1.38 in 2017Q2. It dived, as 56 investors sold Regeneron Pharmaceuticals, Inc. shares while 165 reduced holdings. 71 funds opened positions while 187 raised stakes. 73.70 million shares or 3.04% more from 71.53 million shares in 2017Q2 were reported. Sectoral Asset Mngmt reported 1.9% stake. Fdx Advisors, California-based fund reported 3,868 shares. Valley Natl Advisers holds 0.05% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) or 360 shares. Iberiabank Corp holds 0.36% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 4,793 shares. Baillie Gifford & owns 5,500 shares. Winslow Evans Crocker invested in 802 shares. Moreover, Glg Ltd Liability Com has 0.18% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 6,327 shares. Comerica Comml Bank holds 0.09% or 31,355 shares in its portfolio. Millennium Mgmt Lc invested 0.14% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Bennicas And Assocs owns 1,900 shares. 676 were accumulated by Tokio Marine Asset Management Limited. 10,148 are owned by Sg Americas Secs Limited Com. Proshare Advisors Llc stated it has 99,787 shares. Cornerstone reported 0.22% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). 750 were accumulated by Money Management Limited Com.